Welcome to this week's digest. For May 4 to May 8, 2026, the focus is on modality-defining approvals, AI-enabled discovery infrastructure, radioligand regulatory signals, and competitive pressure around inclisiran. Key items include the first approved PROTAC, the first dual-AAV gene therapy, a pending PET cGMP rule refresh, and new open-source medical AI infrastructure.
Merck and Mayo Clinic's February 2026 collaboration is now operational through Mayo Clinic Platform Orchestrate, combining de-identified genomic sequences, longitudinal clinical records, imaging, and molecular data to support AI-enabled virtual cell models. Initial work includes autoimmune disease and multiple sclerosis.
Why it matters: The collaboration gives a global pharma company access to real-world multimodal clinical data for target identification, moving AI-guided discovery beyond synthetic benchmarks and toward hypotheses pre-validated against patient-level phenotypes.
Source: Merck and Mayo Clinic announcement →Iterative Health closed a $77 million Series C led by Google Ventures and Intrepid Growth Partners, bringing total funding above $270 million and valuing the company at roughly $1.3 billion. Its AI trial platform now links more than 100 research sites across four continents with 40-plus pharma, biotech, and CRO partners, and is expanding from GI into cardiology and obesity.
Why it matters: The raise validates AI-powered community trial networks as clinical development infrastructure, especially in crowded areas such as GLP-1/GIP, cardiometabolic, oncology, and RLT-adjacent trials where enrollment bottlenecks remain material.
Source: BusinessWire →Michigan State University researchers published GPS, a Gene Expression Profile Predictor on Chemical Structures, in Cell. The model predicts compound-induced gene expression changes from chemical structure alone and identified candidate compounds for hepatocellular carcinoma and idiopathic pulmonary fibrosis in validation work.
Why it matters: GPS represents upstream AI discovery with translational potential: it can prioritize de novo or repurposed compounds before wet-lab screening and may accelerate oncology pipeline triage.
Source: HealthcareDiscovery.ai synthesis →FDA granted accelerated approval to Regeneron's Otarmeni (lunsotogene parvec-cwha) on April 23, 2026, for severe-to-profound sensorineural hearing loss caused by biallelic OTOF variants. The therapy uses a dual AAV design because the OTOF payload exceeds single-vector capacity, and the application was reviewed in 61 days under the Commissioner's National Priority Voucher pilot program.
Why it matters: Otarmeni is a technical milestone for large-gene payload delivery and a regulatory milestone for rapid review of complex gene therapy submissions. Continued approval depends on durability of hearing benefit and speech-development outcomes.
Source: FDA press announcement →Intellia's in vivo CRISPR therapy lonvuran ziclumeran (lonvo-z), targeting KLKB1 for hereditary angioedema, met its Phase 3 primary endpoint. A single infusion reduced swelling attack frequency by 87% versus placebo over six months, with 62% of treated patients attack-free compared with 11% on placebo.
Why it matters: Lonvo-z is the first in vivo CRISPR therapy to reach rolling FDA submission, making durability, safety monitoring, and review precedent important signals for the wider genome-editing field.
Source: Reuters →FDA CBER issued draft guidance in April 2026 outlining nonclinical safety evaluation expectations for ex vivo and in vivo genome-editing products. The framework covers NGS-based off-target assessment and applies to CRISPR, base-editing, and prime-editing platforms.
Why it matters: Together with the February 2026 plausible mechanism pathway draft, the guidance begins to define a more coherent regulatory architecture for personalized and bespoke gene therapies, including pre-IND safety packages.
Source: Clinical Trials Arena →McGuireWoods' Q1 2026 radiopharmaceutical update reports that FDA is expected to issue a Notice of Proposed Rulemaking in May 2026 to amend 21 CFR Part 212 for PET drug cGMPs. The update is expected to remove an outdated USP chapter reference and streamline requirements across production, QA, holding, and distribution for PET drugs, including investigational and research PET drugs.
Why it matters: This would be the first substantive Part 212 refresh since 2011 and could affect IND-enabling packages for diagnostic and theranostic PET tracers, including expectations around precursor identity testing and inspection consistency.
Source: McGuireWoods radiopharmaceutical industry update →Novartis confirmed that, based on FDA feedback, it plans to submit PSMAddition Phase 3 data for regulatory review in the second half of 2026. The mHSPC trial met its primary endpoint, with Pluvicto plus standard of care reducing risk of radiographic progression or death by 28% versus standard of care alone and showing a positive overall survival trend.
Why it matters: Approval would move Pluvicto into the earliest metastatic prostate cancer setting and could substantially expand the eligible patient population, changing competitive enrollment dynamics for PSMA/RLT studies.
Source: Novartis →ARTBIO's Phase 1 ARTISAN trial is enrolling patients with metastatic castration-resistant prostate cancer into two cohorts for AB001, a Lead-212 PSMA-targeted alpha radioligand therapy: one cohort with prior Lu-177-PSMA exposure and one without. Expansion outside the United States is planned for the second half of 2026.
Why it matters: Alpha emitters offer higher linear energy transfer and shorter tissue range than beta emitters, making AB001 an important next-generation program to watch for micrometastatic or Lu-177-refractory PSMA-positive disease.
Source: Cancer Network →A May 2026 report describes DNA-based aptamer molecules that inhibit PCSK9 and reduced LDL-C by approximately 50% in preclinical models. The structured DNA molecules bind PCSK9 and block its interaction with LDL receptors.
Why it matters: Although still preclinical, the work shows continued diversification of PCSK9 inhibition beyond antibodies, siRNA, and small binding proteins, and could represent a lower-cost future modality if translation holds.
Source: ScienceDaily and University of Barcelona →LIB Therapeutics' LEROCHOL (lerodalcibep-liga) received FDA approval in December 2025 and is entering its spring 2026 U.S. launch phase. The third-generation PCSK9 small binding protein is administered monthly and showed sustained LDL-C reductions of 56% to 60% in the Phase 3 LIBerate-HR program across more than 2,900 patients.
Why it matters: Monthly self-administration and room-temperature stability make LEROCHOL a meaningful access and adherence competitor to inclisiran, particularly while inclisiran uptake remains below early NHS projections and ORION-4 outcomes data are still awaited.
Source: LIB Therapeutics →A January 2026 systematic review and meta-analysis in BMC Cardiovascular Disorders consolidated Phase 3 ORION data, reporting approximately 50% to 56% LDL-C reductions at 17 months with a consistent safety profile and durable twice-yearly dosing effect.
Why it matters: The key unresolved question remains cardiovascular hard outcomes. ORION-4 data expected in 2026 could materially strengthen inclisiran's clinical and commercial position if positive.
Source: BMC Cardiovascular Disorders via PMC →FDA approved vepdegestrant (Veppanu; Arvinas/Pfizer) on May 1, 2026, for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. The oral PROTAC protein degrader was approved ahead of its June 5 PDUFA date after VERITAC-2 showed a 43% reduction in risk of disease progression or death versus fulvestrant in ESR1-mutated patients.
Why it matters: Veppanu validates PROTACs as an approved therapeutic modality, shifting targeted therapy from inhibition to targeted protein degradation through the ubiquitin-proteasome system and likely accelerating investment across oncology and other disease areas.
Source: HMP Global Learning Network →Regeneron's Otarmeni approval is also a broader regulatory milestone: a complex dual-vector gene therapy reviewed in 61 days under the Commissioner's National Priority Voucher pilot program.
Why it matters: The review cycle shows that highly complex gene therapy and combination-product submissions can move rapidly when sponsor preparation and cross-office FDA coordination are strong.
Source: FDA press announcement →United Imaging Intelligence released uAI NEXUS MedVLM as a fully open-source medical video large language model, with CVPR 2026 acceptance. The release includes model weights, training code, and a medical video benchmark for spatial and temporal clinical video analysis.
Why it matters: The model targets dynamic medical imaging and procedural footage rather than static image interpretation alone, making it relevant to fluoroscopy, nuclear medicine dynamic imaging, endoscopy, surgical video, theranostic workflow analysis, and dynamic PET reconstruction.
Source: AI-Watch Japan →The Open Wearables project offers a Docker-deployable, self-hosted API that unifies data from Garmin, Apple Health, Oura, Whoop, Strava, Polar, Suunto, and Samsung Health. It includes AI-ready schemas, MCP integration, and open-source health scoring algorithms for metrics such as HRV, sleep, recovery, and VO2 max.
Why it matters: For decentralized clinical trials, Open Wearables could provide an auditable open-source layer for wearable data collection and analysis without vendor lock-in.
Source: Open Wearables on GitHub →A Swedish research group published an end-to-end framework for privacy-preserving synthetic health data generation in npj Digital Medicine. TabSyn with a CorrDst loss function outperformed existing approaches across 26 biobank datasets spanning three regulatory data-protection levels.
Why it matters: Synthetic health data is an enabling layer for federated model training, cross-institutional trial data sharing, and regulatory data workflows where direct transfer of patient-level data is constrained.
Source: npj Digital Medicine →ASTRO 2025 commentary on LUNAR highlighted that adding a PSMA-targeting radioligand to metastasis-directed radiation significantly delayed progression in recurrent oligometastatic prostate cancer, extending median rPFS to 17.6 months versus 7.4 months with SBRT alone.
Why it matters: The signal supports studying RLT earlier in the prostate cancer disease course, before hormonal therapy and before the late-line settings where radioligands have historically been concentrated.
Source: ecancer coverage of ASTRO 2025 →In announcing Otarmeni, FDA emphasized that the National Priority Voucher pilot can accelerate rare-disease therapies while coordinating review of complex submissions such as dual-vector gene therapies and combination products across multiple offices and centers.
Why it matters: The message is a direct signal that FDA intends to use coordinated accelerated pathways for selected high-unmet-need therapies without excluding technically complex products.
Source: FDA press announcement →Merck framed its Mayo Clinic collaboration around integrating high-quality clinical data and AI-enabled insights into discovery research to improve target identification and raise the probability of program success.
Why it matters: The statement captures pharma's shift toward discovery models trained against real-world clinical phenotypes, not only molecular assays or simulated data.
Source: Merck →ARTBIO's CMO described AB001 PSMA-targeted radioligand therapy as a potential new treatment pathway for patients with metastatic CRPC who need additional options.
Why it matters: The comment reinforces industry focus on alpha-emitter RLT as a next step for PSMA-positive disease, including settings where Lu-177 exposure or resistance may shape trial design.
Source: Cancer Network →FDA's February 2026 draft framework describes a pathway for personalized CRISPR therapies that differ mainly by guide RNA, with commentary in Nature outlining how development could become faster and less expensive for ultra-rare disease settings.
Why still relevant: The approach may influence adaptive evidence packages and preclinical logic across targeted medicine programs, including future biomarker-defined oncology or molecular-targeting strategies.
Source: Fierce Biotech →Curium reported pharmacokinetic and dosimetry data for investigational Lu-177 zadavotide guraxetan from ECLIPSE, with projected renal doses supporting protocol amendment from four to six treatment cycles.
Why still relevant: Kidney dosimetry remains one of the most operationally constrained toxicity endpoints in PSMA-targeted RLT trials, and six-cycle safety datasets will influence trial planning and competitive positioning.
Source: BioSpace →FDA lifted the clinical hold on MAGNITUDE-2, the Phase 3 trial of Intellia's in vivo CRISPR TTR gene silencer nexiguran ziclumeran in hereditary transthyretin amyloidosis with polyneuropathy, after protocol amendments including enhanced liver monitoring. A separate cardiomyopathy hold remains.
Why still relevant: Intellia now has multiple in vivo CRISPR programs progressing toward or within pivotal-stage evaluation, and the liver-monitoring framework is relevant to hepatotropic gene-editing and oligonucleotide programs.
Source: Cell and Gene Therapy Insights →Novartis presented PSMAddition data at ESMO 2025 showing a 28% rPFS risk reduction for Pluvicto plus standard of care in mHSPC. FDA submission is now scheduled for H2 2026.
Why still relevant: If approved, Pluvicto could move into a much larger treatment-naive metastatic population, affecting site competition, protocol assumptions, sequencing, and biomarker strategy across PSMA-targeted programs.
Source: Novartis →Google's MedGemma 1.5 and MedASR releases provide open medical imaging and speech-to-text models for research use, with improved support for medical image interpretation and clinical speech workflows.
Why still relevant: MedGemma 1.5 may be useful for PET/SPECT interpretation and dosimetry workflow automation, while MedASR could support clinical documentation systems for RLT site teams.
Source: Google Research →Assign regulatory ownership for tracking the publication date and docket number, because the proposed 21 CFR Part 212 amendment may require formal comment-period response and updates to IND-enabling documentation for diagnostic and therapeutic PET programs.
With Novartis planning H2 2026 FDA submission, assess overlap between current site networks and future mHSPC Pluvicto demand, especially for treatment-naive or earlier-line PSMA-targeted studies.
LEROCHOL's U.S. launch, monthly self-injection, and room-temperature stability address adherence and convenience arguments. Market access and medical affairs messaging should be aligned ahead of ORION-4 outcomes data.
Iterative Health's financing validates AI-enabled community trial networks. Review whether current partners can support comparable pre-screening, site activation, and enrollment acceleration for PSMA-RLT, cardiometabolic, or inclisiran-adjacent programs.
The plausible mechanism and genome-editing safety-testing drafts will shape pre-IND expectations for several years. Teams with gene therapy, oligonucleotide, or genome-editing interests should review and consider formal comments to CBER.